During its investor day meeting, continuous glucose monitoring (CGM) devices maker DexCom, Inc. outlined its plans for its revenue target of $4-$4.5bn by 2025, which is more than double the $1.9bn revenue guidance for 2020.
The majority of the growth will come from Dexcom’s core US intensive insulin business, made up of patients with type...